Trends in management and related outcomes for occult primary breast cancer.

Oct 14, 2024

Experts: M LaBella,R E Lile-King,C B Agala,P M Spanheimer,D W Ollila,K K Gallagher,J M Selfridge

Occult Primary Breast Cancer (OPBC) is a rare clinical condition in which breast cancer is located within the axillary lymph nodes, but no primary tumor is identified in the breast. We evaluated trends of neoadjuvant chemotherapy (NAC) use and subsequent axillary procedures in OPBC as well as outcomes for these patients.
The National Cancer Database was used to identify adult women with cT0N1-3M0 breast cancer between 2012 to 2021 that underwent axillary lymph node surgery. Kaplan-Meier curves were used to evaluate survival between groups.
2759 patients met inclusion criteria. 86.2% underwent ALND alone in 2012, and this decreased to 65.6% in 2021. 4.7% underwent SLNB alone in 2012 and this increased to 16.2% in 2021 (p < 0.001). For patients who had undergone NAC, 46.4% of ALND patients had nodal pathologic complete response (nPCR), compared to 42.7% of SLNB + ALND and 66.4% of SLNB only patients. For patients with nPCR, there was no difference in overall survival (OS) between ALND, SLNB + ALND, and SLNB alone groups (p = 0.9912).
Most OPBC patients were treated with ALND, with a modest increase towards SLNB use during the study period. There was no difference in OS with respect to axillary surgical procedure in our population for those with nPCR after NAC. This suggests that for carefully selected OPBC patients with an excellent clinical response to NAC and negative SLNB, omission of ALND may be considered.

© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Author

admin

View all posts

ABOUT THE EXPERTS

M LaBella,R E Lile-King,C B Agala,P M Spanheimer,D W Ollila,K K Gallagher,J M Selfridge

M LaBella

Department of Surgery, University of North Carolina, Chapel Hill, NC, USA.

Surgical Oncology and Endocrine Surgery, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, Suite 1148, Chapel Hill, NC, 27599-7213, USA.

R E Lile-King

Department of Surgery, University of North Carolina, Chapel Hill, NC, USA.

Surgical Oncology and Endocrine Surgery, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, Suite 1148, Chapel Hill, NC, 27599-7213, USA.

C B Agala

Department of Surgery, University of North Carolina, Chapel Hill, NC, USA.

Surgical Oncology and Endocrine Surgery, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, Suite 1148, Chapel Hill, NC, 27599-7213, USA.

P M Spanheimer

Department of Surgery, University of North Carolina, Chapel Hill, NC, USA.

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.

Surgical Oncology and Endocrine Surgery, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, Suite 1148, Chapel Hill, NC, 27599-7213, USA.

D W Ollila

Department of Surgery, University of North Carolina, Chapel Hill, NC, USA.

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.

Surgical Oncology and Endocrine Surgery, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, Suite 1148, Chapel Hill, NC, 27599-7213, USA.

K K Gallagher

Department of Surgery, University of North Carolina, Chapel Hill, NC, USA.

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.

Surgical Oncology and Endocrine Surgery, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, Suite 1148, Chapel Hill, NC, 27599-7213, USA.

J M Selfridge

Department of Surgery, University of North Carolina, Chapel Hill, NC, USA. Julia_Selfridge@med.unc.edu.

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. Julia_Selfridge@med.unc.edu.

Surgical Oncology and Endocrine Surgery, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, Suite 1148, Chapel Hill, NC, 27599-7213, USA. Julia_Selfridge@med.unc.edu.